Oncology biobank and longitudinal sample collection at NYCBS
Official title: New York Cancer and Blood Specialists: Clinical Biospecimen Collection for Research Use
Run by NY Health d/b/a New York Cancer and Blood Specialists · NCT07543159 · Data updated 2026-11-12
This collects and stores blood, tissue, and health information from adults with cancer, people at higher risk, and healthy donors to help researchers test new cancer tests and treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 900000 (estimated) |
| Sponsor | NY Health d/b/a New York Cancer and Blood Specialists Academic / other |
| Locations | 1 site (Shirley, New York) |
| Status | Recruiting |
| Started | December 23, 2025 |
| Main results expected | October 6, 2035 |
| Study ends | October 6, 2035 |
| Registry record updated | April 24, 2026 |
| Trial ID | NCT07543159 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who can give informed consent, including people with benign conditions, diagnosed or suspected cancer, survivors, high-risk individuals, and healthy donors, are eligible to participate.
✕Probably not a fit
Participants should not expect direct therapeutic benefit from enrollment, and people under 18 or unable to provide informed consent are not eligible and will not benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
New York Cancer and Blood Specialists is running a centralized oncology biorepository that collects biological samples and linked clinical data over time from adults receiving care, people at high risk, survivors, and healthy donors. The protocol is observational and gathers biospecimens such as blood and tissue for DNA/RNA analysis, protein and biomarker work, tissue microarrays, and genome sequencing. Samples are stored with associated clinical information to support longitudinal translational research and diagnostic or therapeutic development. Collections occur under a broad master protocol with additional project-specific eligibility criteria as needed.
Why it matters
Potential benefit: If successful, the biobank could speed discovery and validation of new diagnostic tests and treatments for cancer by providing high-quality samples and data to researchers.
How similar studies have gone: Other institutional and national biobanks have supported successful biomarker and genomic discoveries, although impact depends on the quality and use of collected specimens and data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects must be at least 18 years of age 2. Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent 3. Subjects may or may not have active disease at the time of enrollment 4. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors. Exclusion Criteria: 4\) Subjects not meeting the inclusion criteria Additional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.
Where it's running
-
Nycbs
Shirley, New York, United States Recruiting
Study contacts
- Study coordinator: Andrew Lee, MHA
- Email: Biobanking@nycancer.com
- Phone: 16313935767
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI (Mirai)-guided supplemental MRI to find breast cancer in women at high Mirai risk
This will test whether adding a screening breast MRI finds more cancers in women whose mammograms are flagged as high risk by the Mirai AI model.
-
Community registry for cancer risk assessment and prevention
This study is collecting information from adults at higher risk for cancer to see how we can improve cancer screening and prevention in the community.
-
Collecting data to predict cancer risk in at-risk populations
This study is trying to collect samples and health information from people at higher risk of cancer to see if they can find signs that help predict cancer early on.
-
A program to improve cancer care for the community
This study is trying to improve cancer care for African American patients by collecting health information and biological samples to help develop better treatments tailored to their needs.
-
A program to collect cancer-related samples and data for better cancer care
This study is collecting blood, tissue, and other samples from people with cancer or at risk of it to help improve cancer care and treatment in the future.
-
Partnership with patients at risk of cancer
This study is collecting blood, tissue, and other samples from cancer patients and those at risk to see how it can help improve cancer care and support future research.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.